REN and endothelial dysfunction: Given that standard pharmacologic management with renin-angiotensin-aldosterone inhibitors, while essential for reducing intraglomerular pressure and proteinuria, does not fully address persistent OS and endothelial dysfunction, there is a compelling rationale to explore complementary strategies.